Do locoregional recurrence and survival outcomes differ in women with node-negative, HER2-positive breast cancer treated with breast-conserving therapy versus mastectomy?

被引：2
|
作者：
Peterson, David John
Truong, Pauline
Sadek, Betro
Shenouda, Mina
Taghian, Alphonse
Alexander, Cheryl
机构：
[1] British Columbia Canc Agcy, Victoria, BC, Canada
[2] Harvard Univ, Massachusetts Gen Hosp, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 26期
关键词：
D O I：
10.1200/jco.2013.31.26_suppl.69
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
69
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Locoregional recurrence and survival of breast-conserving surgery compared to mastectomy following neoadjuvant chemotherapy in operable breast cancer
    Lv, Fa-you
    Mo, Zongming
    Chen, Binjie
    Huang, Zhen
    Mo, Qinguo
    Tan, Qixing
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [22] Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer
    Anderson, Stewart J.
    Wapnir, Irene
    Dignam, James J.
    Fisher, Bernard
    Mamounas, Eleftherios P.
    Jeong, Jong-Hyeon
    Geyer, Charles E., Jr.
    Wickerham, D. Lawrence
    Costantino, Joseph P.
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) : 2466 - 2473
  • [23] Clinical Outcomes in Breast Cancer Patients with HER2-Positive, Node-Negative Tumors (≤3 cm)
    Iwamoto, Naoko
    Aruga, Tomoyuki
    Horiguchi, Shinichiro
    BREAST CARE, 2022, 17 (04) : 356 - 362
  • [24] Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer
    McArthur, Heather L.
    Mahoney, Kathleen M.
    Morris, Patrick G.
    Patil, Sujata
    Jacks, Lindsay M.
    Howard, Jane
    Norton, Larry
    Hudis, Clifford A.
    CANCER, 2011, 117 (24) : 5461 - 5468
  • [25] Breast-conserving Therapy Achieves Equivalent Locoregional Outcomes Compared to Mastectomy in Women With T1-2N0 Triple Negative Breast Cancer
    Zumsteg, Z. S.
    Morrow, M.
    Arnold, B.
    Zheng, J.
    Zhang, Z.
    Robson, M.
    Brogi, E.
    McCormick, B.
    Powell, S. N.
    Ho, A. Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S188 - S189
  • [26] Breast-Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T1-2N0 Triple-Negative Breast Cancer
    Zachary S. Zumsteg
    Monica Morrow
    Brittany Arnold
    Junting Zheng
    Zhigang Zhang
    Mark Robson
    Tiffany Traina
    Beryl McCormick
    Simon Powell
    Alice Y. Ho
    Annals of Surgical Oncology, 2013, 20 : 3469 - 3476
  • [27] Breast-Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T1-2N0 Triple-Negative Breast Cancer
    Zumsteg, Zachary S.
    Morrow, Monica
    Arnold, Brittany
    Zheng, Junting
    Zhang, Zhigang
    Robson, Mark
    Traina, Tiffany
    McCormick, Beryl
    Powell, Simon
    Ho, Alice Y.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (11) : 3469 - 3476
  • [28] Optimal adjuvant therapy for small node-negative HER2-positive breast cancer in clinical practice
    Osako, T.
    Nishimura, R.
    Nishiyama, Y.
    Okumura, Y.
    Fujisue, M.
    Arima, N.
    BREAST, 2017, 32 : S25 - S25
  • [29] TRIPLE-NEGATIVE OR HER2-POSITIVE STATUS PREDICTS HIGHER RATES OF LOCOREGIONAL RECURRENCE IN NODE-POSITIVE BREAST CANCER PATIENTS AFTER MASTECTOMY
    Wang, Shu-Lian
    Li, Ye-Xiong
    Song, Yong-Wen
    Wang, Wei-Hu
    Jin, Jing
    Liu, Yue-Ping
    Liu, Xin-Fan
    Yu, Zi-Hao
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (04): : 1095 - 1101
  • [30] Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer
    Veitch, Zachary
    Khan, Omar F.
    Tilley, Derek
    Ribnikar, Domek
    Kostaras, Xanthoula
    King, Karen
    Tang, Patricia
    Lupichuk, Sasha
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (01): : 47 - 56
12345